Nicolas Durier
Overview
Explore the profile of Nicolas Durier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chen M, Wong W, Law M, Kiertiburanakul S, Yunihastuti E, Merati T, et al.
PLoS One
. 2016 Mar;
11(3):e0150512.
PMID: 26933963
Background: We assessed the effects of hepatitis B (HBV) or hepatitis C (HCV) co-infection on outcomes of antiretroviral therapy (ART) in HIV-infected patients enrolled in the TREAT Asia HIV Observational...
12.
Jeong S, Italiano C, Chaiwarith R, Ng O, Vanar S, Jiamsakul A, et al.
AIDS Res Hum Retroviruses
. 2015 Sep;
32(3):255-61.
PMID: 26414065
Many HIV-infected individuals do not enter health care until late in the infection course. Despite encouraging earlier testing, this situation has continued for several years. We investigated the prevalence of...
13.
Jiamsakul A, Chaiwarith R, Durier N, Sirivichayakul S, Kiertiburanakul S, Van den Eede P, et al.
J Med Virol
. 2015 Jul;
88(2):234-43.
PMID: 26147742
HIV drug resistance assessments and interpretations can be obtained from genotyping (GT), virtual phenotyping (VP) and laboratory-based phenotyping (PT). We compared resistance calls obtained from GT and VP with those...
14.
Boettiger D, Kerr S, Ditangco R, Chaiwarith R, Li P, Merati T, et al.
Antivir Ther
. 2015 Jun;
21(1):27-35.
PMID: 26069150
Background: The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. Methods: HBV surface...
15.
Boettiger D, Nguyen V, Durier N, Bui H, Heng Sim B, Azwa I, et al.
J Acquir Immune Defic Syndr
. 2015 Jan;
68(2):186-95.
PMID: 25590271
Background: Roughly 4% of the 1.25 million patients on antiretroviral therapy (ART) in Asia are using second-line therapy. To maximize patient benefit and regional resources, it is important to optimize...
16.
Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, et al.
Hepatology
. 2015 Jan;
62(1):31-9.
PMID: 25581111
Unlabelled: In resource-constrained countries where the prevalence of hepatitis C virus (HCV) disease is usually high, it is important to know which population should be treated first in order to...
17.
Heiden D, Saranchuk P, Tun N, Audoin B, Cohn J, Durier N, et al.
Lancet Glob Health
. 2014 Aug;
2(2):e76-7.
PMID: 25104662
No abstract available.
18.
Kariminia A, Durier N, Jourdain G, Saghayam S, Do C, Van Nguyen L, et al.
J Acquir Immune Defic Syndr
. 2014 May;
67(1):71-6.
PMID: 24872132
Objective: To evaluate the value of time-updated weight and height in predicting clinical progression, and immunological and virological failure in children receiving combination antiretroviral therapy (cART). Methods: We used Cox...
19.
Kiertiburanakul S, Boettiger D, Lee M, Omar S, Tanuma J, Ng O, et al.
J Int AIDS Soc
. 2014 Mar;
17:18804.
PMID: 24598459
Introduction: Although antiretroviral therapy (ART) has been rapidly scaled up in Asia, most HIV-positive patients in the region still present with late-stage HIV disease. We aimed to determine trends of...
20.
Fenner L, Ballif M, Graber C, Nhandu V, Dusingize J, Cortes C, et al.
PLoS One
. 2013 Oct;
8(10):e77697.
PMID: 24147059
Objectives: In resource-constrained settings, tuberculosis (TB) is a common opportunistic infection and cause of death in HIV-infected persons. TB may be present at the start of antiretroviral therapy (ART), but...